Literature DB >> 1386300

Bispecific anti-human red blood Rhesus-D antigen x anti Fc gamma RI targeted antibody-dependent cell-mediated cytotoxicity and phagocytosis by mononuclear leucocytes.

E X Deramoudt1, C Gilard, N Lepine, J M Alonso, J L Romet-Lemonne.   

Abstract

The Fc receptor mediated antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis induced by bispecific antibody (BsAb) to the high-affinity Fc receptor for IgG (Fc gamma RI) and to human red blood group antigen RhD were studied in vitro, using human mononuclear leucocytes as effector cells. The results were compared with those obtained by using a human monoclonal IgG1 anti-RhD used alone and a reference human polyclonal anti-RhD antibody. The effect of non-specific human IgG on FcR-mediated functions by mononuclear leucocytes was checked. The results demonstrate that BsAb presents a high resistance of Fc-mediated function to blockade by non-specific human IgG compared with that of both polyclonal and monoclonal anti-RhD antibodies. These results further encourage possible clinical application of bispecific antibody in passive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386300      PMCID: PMC1554448          DOI: 10.1111/j.1365-2249.1992.tb06951.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  ADCC (K-cell)lysis of human erythrocytes sensitized with rhesus alloantibodies. I. Investigation of in vitro culture variables.

Authors:  S J Urbaniak
Journal:  Br J Haematol       Date:  1979-06       Impact factor: 6.998

Review 2.  Further observations on the patterns of clearance of incompatible red cells.

Authors:  P L Mollison
Journal:  Transfusion       Date:  1989-05       Impact factor: 3.157

3.  Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.

Authors:  M A Garrido; M J Valdayo; D F Winkler; J A Titus; T T Hecht; P Perez; D M Segal; J R Wunderlich
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

4.  Monoclonal antibodies to Fc receptors for IgG on human mononuclear phagocytes. Antibody characterization and induction of superoxide production in a monocyte cell line.

Authors:  C L Anderson; P M Guyre; J C Whitin; D H Ryan; R J Looney; M W Fanger
Journal:  J Biol Chem       Date:  1986-09-25       Impact factor: 5.157

5.  Ability of monoclonal anti-D antibodies to promote the binding of red cells to lymphocytes, granulocytes and monocytes.

Authors:  A H Merry; E Brojer; B Zupanska; A G Hadley; B M Kumpel; N C Hughes-Jones
Journal:  Vox Sang       Date:  1989       Impact factor: 2.144

6.  The use of macrophages stimulated by immune interferon as indicator cells in the mononuclear phagocyte assay.

Authors:  E Wiener; S F Garner
Journal:  Clin Lab Haematol       Date:  1987

7.  Measurement of antibody-dependent cell-mediated cytotoxicity by Hb-enzyme release assay (Hb-ERA).

Authors:  J Hou; W F Zheng
Journal:  J Immunol Methods       Date:  1985-12-27       Impact factor: 2.303

8.  Monocyte Fc gamma receptor recognition of cell-bound and aggregated IgG.

Authors:  F Gomez; P Chien; M King; P McDermott; A I Levinson; M D Rossman; A D Schreiber
Journal:  Blood       Date:  1989-08-15       Impact factor: 22.113

9.  Heteroantibody-mediated cytotoxicity: antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-gamma and is not blocked by human IgG.

Authors:  L Shen; P M Guyre; C L Anderson; M W Fanger
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

10.  Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies.

Authors:  B Karpovsky; J A Titus; D A Stephany; D M Segal
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

View more
  1 in total

1.  Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments.

Authors:  F Ramisse; F X Deramoudt; M Szatanik; A Bianchi; P Binder; C Hannoun; J M Alonso
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.